Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Medical ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Gynecologic malignancies.in: Tilstra S.A. Kwolek D. Mitchell J.L. Sex- and gender-based women’s health. Springer International Publishing, Cham, Switzerland2020: 231-255
- Program NCIS. Cancer Stat Facts: Uterine Cancer.(Accessed October 16, 2022)
- Program NCIS. Cancer Stat Facts: Ovarian Cancer.(Accessed October 16, 2022)
- Society AC. Special Section: Rare Cancers in Adults.(Accessed October 16, 2022)
- Epithelial ovarian cancer: An overview.World J Transl Med. 2014; 3: 1-8
- Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.JAMA. 2017; 317: 2402-2416
- Inflammation and ovarian cancer.Cytokine. 2012; 58: 133-147
- The Role of Inflammation and Inflammatory Mediators in the Development, Progression, Metastasis, and Chemoresistance of Epithelial Ovarian Cancer.Cancers. 2018; 10: 251
- The impact of ovulation on fallopian tube epithelial cells: evaluating three hypotheses connecting ovulation and serous ovarian cancer.Endocr Relat Cancer. 2011; 18: 627-642
- Incessant ovulation—a factor in ovarian neoplasia.Lancet. 1971; 298: 163
- Oral contraceptive pills as primary prevention for ovarian cancer: a systematic review and meta-analysis.Obstet Gynecol. 2013; 122: 139-147
- Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls.Lancet. 2008; 371: 303-314
- Symptoms of ovarian cancer.Obstet Gynecol. 2001; 98: 212-217
- Frequency of symptoms of ovarian cancer in women presenting to primary care clinics.JAMA. 2004; 291: 2705-2712
- Development of an ovarian cancer symptom index: possibilities for earlier detection.Cancer. 2007; 109: 221-227
- Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial.Am J Obstet Gynecol. 2005; 193: 1630-1639
- Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis.Am J Obstet Gynecol. 2008; 198: 351-356
- A randomized study of screening for ovarian cancer: a multicenter study in Japan.Int J Gynecol Cancer. 2008; 18: 414-420
- Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial.JAMA. 2011; 305: 2295-2303
- Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial.Lancet. 2016; 387: 945-956
- Accuracy of the pelvic examination in detecting adnexal masses.Obstet Gynecol. 2000; 96: 593-598
- Limitations of the pelvic examination for evaluation of the female pelvic organs.Int J Gynaecol Obstet. 2005; 88: 84-88
- Periodic Screening Pelvic Examination: Evidence Report and Systematic Review for the US Preventive Services Task Force.JAMA. 2017; 317: 954-966
- Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers.Sci Transl Med. 2018; 10: eaap8793
- Screening for Ovarian Cancer: US Preventive Services Task Force Recommendation Statement..JAMA. 2018; 319: 588-594
- Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.J Natl Compr Canc Netw. 2021; 19: 77-102
- Ovarian cancer.in: StatPearls. StatPearls Publishing, 2022 (Available at:) (Accessed May 12, 2022)
- Surgery for advanced epithelial ovarian cancer.Best Pract Res Clin Obstet Gynaecol. 2017; 41: 71-87
- Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer.N Engl J Med. 1996; 334: 1-6
- Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.J Clin Oncol Off J Am Soc Clin Oncol. 2003; 21: 3194-3200
- Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study.J Clin Oncol. 2015; 33: 1460-1466
- Is intraperitoneal chemotherapy still an acceptable option in primary adjuvant chemotherapy for advanced ovarian cancer?.Ann Oncol Off J Eur Soc Med Oncol. 2017; 28: viii40-viii45
- Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study.J Clin Oncol. 2007; 25: 437-443
- Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials.N Engl J Med. 1990; 322: 1021-1027
- Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer.Cochrane Database Syst Rev. 2009; 3: CD004706
- Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.N Engl J Med. 2010; 363: 943-953
- Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer.Cochrane Database Syst Rev. 2012; 8: CD005343
- Latest clinical evidence of maintenance therapy in ovarian cancer.Curr Opin Obstet Gynecol. 2020; 32: 15-21
- PARP inhibitors in ovarian cancer: current status and future promise.Gynecol Oncol. 2014; 133: 362-369
- Exploring and comparing adverse events between PARP inhibitors.Lancet Oncol. 2019; 20: e15-e28
- Bevacizumab and ovarian cancer.Ther Adv Med Oncol. 2013; 5: 133-141
- Bevacizumab toxicities and their management in ovarian cancer.Gynecol Oncol. 2010; 117: 497-504
- Prognostic factors for stage III epithelial ovarian cancer: a gynecologic oncology group study.J Clin Oncol. 2007; 25: 3621-3627
- Prognostic factors in young ovarian cancer patients: an analysis of four prospective phase III intergroup trials of the AGO Study Group, GINECO and NSGO.Eur J Cancer Oxf Engl 1990. 2016; 66: 114-124
- Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis.J Clin Oncol. 2002; 20: 1248-1259
- Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: society of Gynecologic Oncologists recommendations.Am J Obstet Gynecol. 2011; 204: 466-478
- Factors favouring long-term survival following recurrence in ovarian cancer.Mol Clin Oncol. 2017; 7: 42-46
- A study of symptoms described by ovarian cancer survivors.Gynecol Oncol. 2012; 125: 59-64
- Cancer statistics, 2022.CA Cancer J Clin. 2022; 72: 7-33
- Diagnosis and treatment of sarcoma of the uterus. A review.Acta Oncol. 2012; 51: 694-705
- NCCN clinical practice guidelines in oncology: uterine Neoplasms, version 1.2022.NCCN, 2022 (Available at:) (Accessed October 16, 2022)
- Surveillance, epidemiology, and end results program. cancer stat facts: uterine cancer.(Available at:) (Accessed December 12, 2020)
- Executive summary of the uterine cancer evidence review conference.Obstet Gynecol. 2022; 139: 626-643
- Endometrial Cancer Obstet Gynecol. 2012; 120: 383-397
- Integrated genomic characterization of endometrial carcinoma.Nature. 2013; 497: 67-73
- Adiposity and cancer risk: new mechanistic insights from epidemiology.Nat Rev Cancer. 2015; 15: 484-498
- American Cancer Society guidelines for the early detection of cancer: update of early detection guidelines for prostate, colorectal, and endometrial cancers. Also: update 2001–testing for early lung cancer detection.CA Cancer J Clin. 2001; 51: 38-75
- Type I and II endometrial cancers: have they different risk factors?.J Clin Oncol Off J Am Soc Clin Oncol. 2013; 31: 2607-2618
- Risk Factors for Endometrial Cancer or Hyperplasia in Adolescents and Women 25 Years Old or Younger.J Pediatr Adolesc Gynecol. 2019; 32: 546-549
- Meta-analysis of vascular and neoplastic events associated with tamoxifen.J Gen Intern Med. 2003; 18: 937-947
- 601: Tamoxifen and uterine cancer.Obstet Gynecol. 2014; 123: 1394-1397
- Prospective longitudinal study of ultrasound screening for endometrial abnormalities in women with breast cancer receiving tamoxifen.Gynecol Oncol. 2003; 91: 154-159
- Tamoxifen and the endometrium: findings of pelvic ultrasound examination and endometrial biopsy in asymptomatic breast cancer patients.Breast Cancer Res Treat. 1998; 47: 41-46
- Diagnosis and Management of Endometrial Cancer.Am Fam Physician. 2016; 93: 468-474
- Endometrial cancer and Lynch syndrome: clinical and pathologic considerations.Cancer Control J Moffitt Cancer Cent. 2009; 16: 14-22
- Association between diabetes, diabetes treatment and risk of developing endometrial cancer.Br J Cancer. 2014; 111: 1432-1439
- Cancer screening in the United States, 2012: a review of current American Cancer Society guidelines and current issues in cancer screening.CA Cancer J Clin. 2012; 62: 129-142
- Endometrial and ovarian cancer in lynch syndrome.Clin Colon Rectal Surg. 2012; 25: 97-102
- Testing women with endometrial cancer to detect Lynch syndrome.J Clin Oncol. 2011; 29: 2247-2252
- Annual outpatient hysteroscopy and endometrial sampling (OHES) in HNPCC/Lynch syndrome (LS).Arch Gynecol Obstet. 2012; 286: 1555-1562
- The etiology of uterine sarcomas: a pooled analysis of the epidemiology of endometrial cancer consortium.Br J Cancer. 2013; 108: 727-734
- The risk of developing uterine sarcoma after tamoxifen use.Int J Gynecol Cancer. 2008; 18: 352-356
- Postirradiation sarcoma of the gynecologic tract. A report of 13 cases and a discussion of the risk of radiation-induced gynecologic malignancies.Am J Clin Oncol. 1996; 19: 59-64
- Uterine leiomyosarcoma: Epidemiology, contemporary treatment strategies and the impact of uterine morcellation.Gynecol Oncol. 2017; 145: 208-216
- The Growing Burden of Endometrial Cancer: A Major Racial Disparity Affecting Black Women.Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2015; 24: 1407-1415
- Cigarette smoking and the risk of endometrial cancer: a meta-analysis.Am J Med. 2008; 121: 501-508.e3
- Levonorgestrel-releasing intrauterine system use is associated with a decreased risk of ovarian and endometrial cancer, without increased risk of breast cancer. Results from the NOWAC Study.Gynecol Oncol. 2018; 149: 127-132
- Contemporary hormonal contraception and risk of endometrial cancer in women younger than age 50: A retrospective cohort study of Danish women.Contraception. 2020; 102: 152-158
- Modification of the associations between duration of oral contraceptive use and ovarian, endometrial, breast, and colorectal cancers.JAMA Oncol. 2018; 4: 516-521
- Transvaginal ultrasonography of the endometrium in women with postmenopausal bleeding–a Nordic multicenter study.Am J Obstet Gynecol. 1995; 172: 1488-1494
- CA 125 may not reflect disease status in patients with uterine serous carcinoma.Cancer. 1998; 82: 1720-1725
- Use of serum CA 125 measurement in posttreatment surveillance of early-stage endometrial carcinoma.Am J Obstet Gynecol. 1990; 162: 427-429
- Serial serum CA 125 measurements for evaluation of recurrence in patients with endometrial carcinoma.Obstet Gynecol. 1994; 84: 12-16
- Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy.Gynecol Oncol. 2003; 89: 460-469
- A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort study.Lancet Oncol. 2017; 18: 384-392
- Sentinel lymph node mapping and staging in endometrial cancer: A Society of Gynecologic Oncology literature review with consensus recommendations.Gynecol Oncol. 2017; 146: 405-415
- Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2 Study.J Clin Oncol. 2012; 30: 695-700
- Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review.Gynecol Oncol. 2012; 125: 477-482
- Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis.Am J Obstet Gynecol. 2012; 207: 266.e1-12
- Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma.J Clin Oncol. 2015; 33: 930-936
- Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group.J Clin Oncol. 2011; 29: 3278-3285
- Clinical activity and safety of the anti-programmed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair-deficient endometrial cancer: a nonrandomized phase 1 clinical trial.JAMA Oncol. 2020; 6: 1766-1772
- Nivolumab is effective in mismatch repair-deficient noncolorectal cancers: results from arm Z1D-A subprotocol of the NCI-MATCH (EAY131) study.J Clin Oncol. 2020; 38: 214-222
- Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.J Clin Oncol. 2020; 38: 1-10
- Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.Lancet Oncol. 2020; 21: 1353-1365
- Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial.Lancet Oncol. 2019; 20: 711-718
- A nomogram to predict postresection 5-year overall survival for patients with uterine leiomyosarcoma.Cancer. 2012; 118: 660-669
- Utility of PET/CT to evaluate retroperitoneal lymph node metastasis in high-risk endometrial cancer: results of ACRIN 6671/GOG 0233 trial.Radiology. 2017; 283: 450-459
- Uterine Cancer Incidence and Mortality - United States, 1999-2016.MMWR Morb Mortal Wkly Rep. 2018; 67: 1333-1338
- Cancer facts & figures.(Available at:) (Accessed July 1, 2021)
- Endometrial cancer: socioeconomic status and racial/ethnic differences in stage at diagnosis, treatment, and survival.Am J Public Health. 2004; 94: 2104-2111
- Disparities in uterine cancer epidemiology, treatment, and survival among African Americans in the United States.Gynecol Oncol. 2013; 130: 652-659
- Disparities in receipt of care for high-grade endometrial cancer: A National Cancer Data Base analysis.Gynecol Oncol. 2017; 145: 114-121
- Racial disparities in treatment of high-grade endometrial cancer in the Medicare population.Obstet Gynecol. 2015; 125: 843-851
- Differences in treatment and outcome between African-American and white women with endometrial cancer.J Clin Oncol Off J Am Soc Clin Oncol. 2003; 21: 4200-4206
- Racial disparities in surgical care for uterine cancer.Gynecol Oncol. 2011; 121: 571-576
- Black and Hispanic women are less likely than white women to receive guideline-concordant endometrial cancer treatment.Am J Obstet Gynecol. 2020; 223: 398.e1-398.e18
- Impact of quality of care on racial disparities in survival for endometrial cancer.Am J Obstet Gynecol. 2020; 223: 396.e1-396.e13
- Racial-ethnic and socioeconomic disparities in guideline-adherent treatment for endometrial cancer.Obstet Gynecol. 2021; 138: 21-31
- Health disparities in uterine cancer: report from the uterine cancer evidence review conference.Obstet Gynecol. 2022; 139: 645-659
- Descriptive epidemiological study of vaginal cancer using data from the Osaka Japan population-based cancer registry: Long-term analysis from a clinical viewpoint.Medicine (Baltimore). 2017; 96
- Demographic, clinical, and treatment trends among women diagnosed with vulvar cancer in the United States.Gynecol Oncol. 2008; 108: 577-583
- Management and outcomes of primary vaginal Cancer.Gynecol Oncol. 2020; 159: 456-463
- Incidence of in situ and invasive vulvar cancer in the US, 1998-2003.Cancer. 2008; 113: 2865-2872
- Descriptive epidemiology of vaginal cancer incidence and survival by race, ethnicity, and age in the United States.Cancer. 2008; 113: 2873-2882
- Differentiated vulvar intraepithelial neoplasia is often found in lesions, previously diagnosed as lichen sclerosus, which have progressed to vulvar squamous cell carcinoma.Mod Pathol. 2011; 24: 297-305
- Prevalence and type distribution of human papillomavirus in squamous cell carcinoma and intraepithelial neoplasia of the vulva.Int J Cancer. 2017; 141: 1161-1169
- Vaginal and cervical abnormalities after exposure to stilbestrol in utero.Obstet Gynecol. 2003; 102 (Obstet Gynecol 1972;40:287-298): 222
Committee Opinion No.675: Management of Vulvar Intraepithelial Neoplasia published correction appears in Obstet Gynecol. 2017. Obstet Gynecol. 2016;128(4):e178–e182.
- Squamous cell carcinoma of the vagina: natural history, treatment modalities and prognostic factors.Crit Rev Oncol Hematol. 2015; 93: 211-224
- Clinical presentation, treatment and outcome of vaginal intraepithelial neoplasia.Arch Gynecol Obstet. 2016; 293: 415-419
- Vulvar Cancer (Version 1.2022).(Available at:) (Accessed May 22, 2022)
- Impact of race and ethnicity on treatment and survival of women with vulvar cancer in the United States.Gynecol Oncol. 2013; 129: 154-158
- Disparities in Vulvar Cancer Reported by the National Cancer Database: Influence of Sociodemographic Factors.Obstet Gynecol. 2015; 126: 792-802
- Cancer of the vagina.Int J Gynaecol Obstet Off Organ Int Fed Gynaecol Obstet. 2012; 119: S97-S99
- Vaginal cancer.Crit Rev Oncol Hematol. 2012; 81: 286-295
- Patterns of recurrence in patients with squamous cell carcinoma of the vulva. A multicenter CTF Study.Cancer. 2000; 89 (2-4): 116-122
- SEER cancer statistics factsheets: vulvar cancer.(Available at:) (Accessed May 22, 2022)
- Surveillance, Epidemiology, and End Results (SEER) Program Populations (1969-2020).(Available at:) (Accessed May 22, 2022)
- Prediction of persistent vaginal intraepithelial neoplasia in previously hysterectomized women by high-risk HPV DNA detection.Cancer Lett. 2007; 249: 235-241
- An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncology (SGO) recommendations.Gynecol Oncol. 2017; 146: 3-10
- Long-term survival and disease recurrence in patients with primary squamous cell carcinoma of the vulva.Gynecol Oncol. 2005; 97: 828-833
Article info
Publication history
Published online: January 02, 2023
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
